Novartis AG, a Swiss multinational pharmaceutical company, is making strides in the healthcare industry through their extensive research and development of innovative medicines. Their operations consist of two segments, Innovative Medicines and Sandoz. The former offers prescription medicines including cardiovascular, ophthalmology, neuroscience, hematology, and solid tumor products. The latter produces small molecule pharmaceuticals and biotechnology-based products such as biosimilars, and anti-infectives. In addition, the company has secured a license and collaboration agreement with Alnylam Pharmaceuticals to develop and commercialize inclisiran, a therapy designed to reduce LDL cholesterol. Since its inception in 1996, Novartis AG has been committed to improving healthcare on a global scale and is headquartered in the city of Basel, Switzerland.